GBA Group Acquires KaLy-Cell SAS
September 5, 2022
GBA Group has acquired French contract research organization KaLy-Cell SAS, marking the group's market entry into France and expanding its European pharmaceutical network. KaLy-Cell, founded in 2003 as a spin-off from the University of Bourgogne Franche-Comté and headquartered in Plobsheim, provides hepatocyte-based in vitro contract research and safety testing services for pharmaceuticals, agrochemicals and cosmetics.
- Buyers
- GBA Group
- Targets
- KaLy-Cell SAS
- Platforms
- GBA Group
- Industry
- Biotechnology
- Location
- Grand Est, France
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
GBA Group MedTech Solutions acquires majority stake in Johner Institut
March 10, 2026
Healthcare Services
GBA Group MedTech Solutions acquired a majority stake in Johner Institut GmbH to expand its European platform for medical device services. The deal strengthens GBA’s regulatory and technology capabilities and expands its service portfolio in consulting and training, including AI-enabled RegTech approaches.
-
GBA Group Acquires Key2Compliance AB
January 16, 2024
Healthcare Services
GBA Group has acquired Key2Compliance AB to expand its consulting and training services for the medical device, in vitro diagnostics (IVD), and pharmaceutical industries. Key2Compliance, founded in Stockholm in 1994, employs over 70 experts and operates offices in Stockholm, two other Swedish locations and Copenhagen, Denmark, strengthening GBA's capability to offer comprehensive life-science compliance services in the Scandinavian market.
-
KCAS Acquires France-based Active Biomarkers
September 12, 2022
Healthcare Services
KCAS Bioanalytical and Biomarker Services, a Vitruvian Partners-backed CRO headquartered in Olathe, Kansas, has acquired Active Biomarkers, a bioanalytical laboratory based in Lyon, France. The deal, previously owned by the management team and Turenne Santé, expands KCAS's European footprint and adds specialty bioassay and cellular analysis capabilities to support pharma and biotech customers worldwide.
-
Keensight Capital Acquires Majority Stake in BYG4lab
July 22, 2022
Software
Keensight Capital has acquired a majority stake in BYG4lab, a France-headquartered provider of data management software for medical laboratories. The PE firm will support BYG4lab's international expansion (Europe and North America), product diversification and accelerated growth both organically and via acquisitions.
-
Global Cord Blood Corporation Acquires Cellenkos, Inc.
April 29, 2022
Biotechnology
Global Cord Blood Corporation (GCBC) agreed to acquire 100% of clinical-stage biotech Cellenkos, Inc., and worldwide rights to most of its products (excluding those under an Incyte collaboration). The transaction consideration includes approximately 125 million new shares (as-converted) valued at $11 per share plus $664 million in cash; GCBC said the acquisition expands its capabilities into allogeneic T-reg cell therapies and supports global commercialization and R&D.
-
Nexelis Acquires GSK Vaccines Clinical Bioanalytical Laboratory (Marburg)
January 20, 2021
Biotechnology
Nexelis, a portfolio company of Ampersand Capital Partners, has signed an asset purchase agreement to acquire GSK's GCLP-certified clinical bioanalytical laboratory in Marburg, Germany. Approximately 80 scientists and analysts will transfer to Nexelis, which also entered a five-year strategic collaboration with GSK to continue supporting vaccine development while expanding Nexelis' assay development and high-throughput clinical testing capabilities in Europe.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.